Marco Sciveres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marco Sciveres has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Maggiore
Hepatogastroenterology, Nutrition and Liver Transplant Unit, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy
25 shared publications G. Maggiore
11 shared publications- Marco Spada
Division of Hepatobiliopancreatic Surgery, Liver and Kidney Transplantation Bambino Gesù Children's Hospital IRCCS Rome Italy
8 shared publications S. Riva
7 shared publicationsSilvia Riva
Pediatric Hepatology and Liver Transplantation, ISMETT UPMC Palermo, Palermo, Italy
6 shared publications- Lorenzo D’ Antiga
Pediatric Hepatology, Gastroenterology and Transplantation, ASST Papa Giovanni XXIII Bergamo Italy
5 shared publications
Latest Publications
- 14 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10)
Optimized Cytomegalovirus‐ DNA Threshold for Preemptive Therapy in Pediatric Liver Transplant Recipients: A Mixed‐Effects Model‐Based Analysis of Prospective Cohort Data
Background: Cytomegalovirus (CMV) remains one of the most significant infectious complications after pediatric liver transplantation (LT). Although preemptive therapy (PET) is an effective and widely supported strategy, the choice of a clinically actionable CMV‐DNA threshold varies substantially among centers. We aimed to evaluate below‐standard CMV‐DNA thresholds able to accurately predict clinically significant infection (CSI) while preventing overtreatment in children after LT. Methods: In this prospective observational study, 66 children were followed for 6 months post‐LT with scheduled whole‐blood CMV‐DNA monitoring. CMV‐DNA trajectories were evaluated using mixed‐effects spline models and compared by clinical outcome and serologic risk. Threshold performance was assessed through interpolated viral‐load curves for all infected patients. Sensitivity, overtreatment rate, and positive predictive value (PPV) were estimated for the candidate thresholds. Results: CSI occurred in 19/66 patients (28.7%), while 28 had abortive infections (AI), and 19 showed no infection. CSI displayed significantly higher and more sustained CMV‐DNA trajectories compared with AI ( p < 0.0001). Serologic risk did not modify viral kinetics. Threshold analysis identified 40 000 IU/mL (57 140 copies/mL) as the optimal PET cut‐off: it treated all CSI cases (sensitivity 94.7%, 95% CI 88.9–100), resulted in no overtreatment, and maintained high PPV (100%). Lower thresholds increased overtreatment (up to > 50%), while higher ones added no clinical advantage. Conclusions: A CMV‐DNA threshold of 40 000 IU/mL in whole blood optimally balances timely PET initiation with avoidance of unnecessary antiviral therapy. These findings support a standardized, clinically pragmatic approach to PET in pediatric LT.
- 14 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10)
Optimized Cytomegalovirus‐ DNA Threshold for Preemptive Therapy in Pediatric Liver Transplant Recipients: A Mixed‐Effects Model‐Based Analysis of Prospective Cohort Data
Background: Cytomegalovirus (CMV) remains one of the most significant infectious complications after pediatric liver transplantation (LT). Although preemptive therapy (PET) is an effective and widely supported strategy, the choice of a clinically actionable CMV‐DNA threshold varies substantially among centers. We aimed to evaluate below‐standard CMV‐DNA thresholds able to accurately predict clinically significant infection (CSI) while preventing overtreatment in children after LT. Methods: In this prospective observational study, 66 children were followed for 6 months post‐LT with scheduled whole‐blood CMV‐DNA monitoring. CMV‐DNA trajectories were evaluated using mixed‐effects spline models and compared by clinical outcome and serologic risk. Threshold performance was assessed through interpolated viral‐load curves for all infected patients. Sensitivity, overtreatment rate, and positive predictive value (PPV) were estimated for the candidate thresholds. Results: CSI occurred in 19/66 patients (28.7%), while 28 had abortive infections (AI), and 19 showed no infection. CSI displayed significantly higher and more sustained CMV‐DNA trajectories compared with AI ( p < 0.0001). Serologic risk did not modify viral kinetics. Threshold analysis identified 40 000 IU/mL (57 140 copies/mL) as the optimal PET cut‐off: it treated all CSI cases (sensitivity 94.7%, 95% CI 88.9–100), resulted in no overtreatment, and maintained high PPV (100%). Lower thresholds increased overtreatment (up to > 50%), while higher ones added no clinical advantage. Conclusions: A CMV‐DNA threshold of 40 000 IU/mL in whole blood optimally balances timely PET initiation with avoidance of unnecessary antiviral therapy. These findings support a standardized, clinically pragmatic approach to PET in pediatric LT.
- Open Access
- 23 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (12) , 1583-1587
Early predictors of pruritus response in children with PFIC treated with odevixibat
- 23 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (12) , 1583-1587
Open AccessEarly predictors of pruritus response in children with PFIC treated with odevixibat
- Open Access
- 27 July 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (8)
Artificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study
Background: Autoimmune hepatitis (AIH) is an important indication for liver transplantation (LT), but recurrence affects over 30% of recipients, threatening long-term survival. Current strategies to prevent recurrence and progressive graft fibrosis remain suboptimal, with limited evidence to guide selection of immunosuppressive regimens. We aimed to develop a dynamic, individualized, artificial intelligence–powered model for post-transplant recurrent AIH. Methods: We conducted a multicenter, retrospective cohort study of 706 patients who underwent LT for AIH between January 1987 and June 2020 at 33 centers in North America, South America, Europe, and Asia. We trained 4 predictive machine learning models—Logistic Regression, Random Forest, XGBoost, and Gradient Boost—to predict recurrent AIH (rAIH) using 62 clinical and laboratory variables, including demographic, biochemical features, and immunosuppressive drugs up to 1-year post-transplant. Feature importance was assessed using SHapley Additive exPlanations (SHAP) to enable interpretability at both individual and population levels. Results: AIH recurred in 16.5% of patients after LT. SHAP analysis identified younger age at LT, higher necroinflammatory activity in the explanted liver, and elevated MELD score at LT as key predictors of rAIH in the overall population. Tacrolimus-based therapy was associated with a lower risk of recurrence, while cyclosporine use conferred a higher risk. The addition of long-term prednisone to a regimen of tacrolimus and mycophenolate mofetil did not provide additional protective effect against rAIH. Conclusions: Our AI-powered clinical decision model provides personalized prediction of post-transplant rAIH. While it offers insight into modifiable and non-modifiable predictors, prospective validation is required before informing immunosuppressive decisions.
- 27 July 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (8)
Open AccessArtificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study
Background: Autoimmune hepatitis (AIH) is an important indication for liver transplantation (LT), but recurrence affects over 30% of recipients, threatening long-term survival. Current strategies to prevent recurrence and progressive graft fibrosis remain suboptimal, with limited evidence to guide selection of immunosuppressive regimens. We aimed to develop a dynamic, individualized, artificial intelligence–powered model for post-transplant recurrent AIH. Methods: We conducted a multicenter, retrospective cohort study of 706 patients who underwent LT for AIH between January 1987 and June 2020 at 33 centers in North America, South America, Europe, and Asia. We trained 4 predictive machine learning models—Logistic Regression, Random Forest, XGBoost, and Gradient Boost—to predict recurrent AIH (rAIH) using 62 clinical and laboratory variables, including demographic, biochemical features, and immunosuppressive drugs up to 1-year post-transplant. Feature importance was assessed using SHapley Additive exPlanations (SHAP) to enable interpretability at both individual and population levels. Results: AIH recurred in 16.5% of patients after LT. SHAP analysis identified younger age at LT, higher necroinflammatory activity in the explanted liver, and elevated MELD score at LT as key predictors of rAIH in the overall population. Tacrolimus-based therapy was associated with a lower risk of recurrence, while cyclosporine use conferred a higher risk. The addition of long-term prednisone to a regimen of tacrolimus and mycophenolate mofetil did not provide additional protective effect against rAIH. Conclusions: Our AI-powered clinical decision model provides personalized prediction of post-transplant rAIH. While it offers insight into modifiable and non-modifiable predictors, prospective validation is required before informing immunosuppressive decisions.
- Open Access
- 3 February 2026
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (1) , 19
Pediatric Cholestatic Diseases in the Era of Ileal Bile Acid Transporter (IBAT) Inhibitors
Cholestatic diseases in children represent a heterogeneous group of disorders that, with few exceptions, have no cure. For decades, off-label drugs and/or drugs with little evidence of efficacy have been used to treat pruritus or as supportive therapy. In recent years, a family of molecules known as bile acid transporter inhibitors (IBATis) has been developed, with two of these being approved for treating pruritus in progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Blocking the ileal reabsorption of bile acids (BAs) lowers serum levels. This contributes to reducing cholestatic pruritus. Such a mechanism of action may also have a potential benefit in other cholestatic diseases and even in the consequences of chronic cholestasis. This is a narrative review of the literature, including the most recent communications, to summarize data on the efficacy and safety of IBATis in the treatment of pruritus in PFIC and ALGS in children, including a description of the latest results from their use in a real-world setting. Reports on off-label use and experiences in adults are also discussed. This review aims to help physicians understand the potential and limitations of these new drugs in the treatment of cholestatic pruritus.
- 3 February 2026
- Published by MDPI AG in Pediatric Reports
- Vol. 18 (1) , 19
Open AccessPediatric Cholestatic Diseases in the Era of Ileal Bile Acid Transporter (IBAT) Inhibitors
Cholestatic diseases in children represent a heterogeneous group of disorders that, with few exceptions, have no cure. For decades, off-label drugs and/or drugs with little evidence of efficacy have been used to treat pruritus or as supportive therapy. In recent years, a family of molecules known as bile acid transporter inhibitors (IBATis) has been developed, with two of these being approved for treating pruritus in progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). Blocking the ileal reabsorption of bile acids (BAs) lowers serum levels. This contributes to reducing cholestatic pruritus. Such a mechanism of action may also have a potential benefit in other cholestatic diseases and even in the consequences of chronic cholestasis. This is a narrative review of the literature, including the most recent communications, to summarize data on the efficacy and safety of IBATis in the treatment of pruritus in PFIC and ALGS in children, including a description of the latest results from their use in a real-world setting. Reports on off-label use and experiences in adults are also discussed. This review aims to help physicians understand the potential and limitations of these new drugs in the treatment of cholestatic pruritus.
- Open Access
Primary and Secondary Prophylaxis of Gastrointestinal Bleeding in Children with Portal Hypertension: A Multicenter National Study by SIGENP
Background/Objectives: Portal hypertension (PH) is a common complication in children with chronic liver diseases. Primary and secondary prophylaxis of variceal bleeding in these patients remains controversial. Our study aims to evaluate the management of gastrointestinal (GI) varices in children with PH in Italy. Methods: A questionnaire was sent to 21 major pediatric hepatology centers. It included 34 questions referring to the medical, endoscopic, radiological, and surgical management of GI varices. Results: Out of 21 centers, 16 returned a completed questionnaire (survey response rate 76%) with a high level of completeness. A total of 1206 children with PH were under follow-up. Splenomegaly associated with hypersplenism was the main indication for endoscopic surveillance in all centers (100%). Primary prophylaxis was performed with endoscopy plus non-selective beta-blockers (NSBBs) in 50%, endoscopy alone in 38%, and NSBBs alone in 12%. All centers managed acute variceal bleeding with endoscopy within 24 h, acid suppression, and octreotide infusion. Secondary prophylaxis of variceal bleeding was conducted using endoscopy (100%) and NSBBs (87%). Transjugular intrahepatic portosystemic shunt (TIPS) was considered a good option when endoscopic treatment failed in 94% of centers. Conclusions: In Italy, there is broad consensus among centers regarding the management of gastrointestinal varices in children with portal hypertension. All participating centers endorsed the use of endoscopic screening for children presenting with clinical signs of portal hypertension. Nonetheless, further research is essential to establish evidence-based guidelines and to improve overall quality of care.
Open AccessPrimary and Secondary Prophylaxis of Gastrointestinal Bleeding in Children with Portal Hypertension: A Multicenter National Study by SIGENP
Background/Objectives: Portal hypertension (PH) is a common complication in children with chronic liver diseases. Primary and secondary prophylaxis of variceal bleeding in these patients remains controversial. Our study aims to evaluate the management of gastrointestinal (GI) varices in children with PH in Italy. Methods: A questionnaire was sent to 21 major pediatric hepatology centers. It included 34 questions referring to the medical, endoscopic, radiological, and surgical management of GI varices. Results: Out of 21 centers, 16 returned a completed questionnaire (survey response rate 76%) with a high level of completeness. A total of 1206 children with PH were under follow-up. Splenomegaly associated with hypersplenism was the main indication for endoscopic surveillance in all centers (100%). Primary prophylaxis was performed with endoscopy plus non-selective beta-blockers (NSBBs) in 50%, endoscopy alone in 38%, and NSBBs alone in 12%. All centers managed acute variceal bleeding with endoscopy within 24 h, acid suppression, and octreotide infusion. Secondary prophylaxis of variceal bleeding was conducted using endoscopy (100%) and NSBBs (87%). Transjugular intrahepatic portosystemic shunt (TIPS) was considered a good option when endoscopic treatment failed in 94% of centers. Conclusions: In Italy, there is broad consensus among centers regarding the management of gastrointestinal varices in children with portal hypertension. All participating centers endorsed the use of endoscopic screening for children presenting with clinical signs of portal hypertension. Nonetheless, further research is essential to establish evidence-based guidelines and to improve overall quality of care.
- Open Access
- 20 December 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (4) , 101309
Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis
- 20 December 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (4) , 101309
Open AccessReal-world experience with odevixibat in children with progressive familial intrahepatic cholestasis
- Open Access
- 1 February 2024
- Published by MDPI AG in Pediatric Reports
- Vol. 16 (1) , 110-113
Pediatric Autoimmune Hepatitis
Pediatric autoimmune hepatitis (PAIH) is a rare necro-inflammatory disease of the liver of unknown etiology thought to derive from the dysregulation of the immune response upon exposure to environmental triggers in genetically predisposed individuals
- 1 February 2024
- Published by MDPI AG in Pediatric Reports
- Vol. 16 (1) , 110-113
Open AccessPediatric Autoimmune Hepatitis
Pediatric autoimmune hepatitis (PAIH) is a rare necro-inflammatory disease of the liver of unknown etiology thought to derive from the dysregulation of the immune response upon exposure to environmental triggers in genetically predisposed individuals
- Open Access
- 24 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (17) , 2753
Juvenile Autoimmune Hepatitis: Recent Advances in Diagnosis, Management and Long-Term Outcome
Juvenile autoimmune hepatitis (JAIH) is severe immune-mediated necro-inflammatory disease of the liver with spontaneous progression to cirrhosis and liver failure if left untreated. The diagnosis is based on the combination of clinical, laboratory and histological findings. Prothrombin ratio is a useful prognostic factor to identify patients who will most likely require a liver transplant by adolescence or early adulthood. JAIH treatment consists of immune suppression and should be started promptly at diagnosis to halt inflammatory liver damage and ultimately prevent fibrosis and progression to end-stage liver disease. The risk of relapse is high especially in the setting of poor treatment compliance. Recent evidence however suggests that treatment discontinuation is possible after a prolonged period of normal aminotransferase activity without the need for liver biopsy prior to withdrawal.
- 24 August 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (17) , 2753
Open AccessJuvenile Autoimmune Hepatitis: Recent Advances in Diagnosis, Management and Long-Term Outcome
Juvenile autoimmune hepatitis (JAIH) is severe immune-mediated necro-inflammatory disease of the liver with spontaneous progression to cirrhosis and liver failure if left untreated. The diagnosis is based on the combination of clinical, laboratory and histological findings. Prothrombin ratio is a useful prognostic factor to identify patients who will most likely require a liver transplant by adolescence or early adulthood. JAIH treatment consists of immune suppression and should be started promptly at diagnosis to halt inflammatory liver damage and ultimately prevent fibrosis and progression to end-stage liver disease. The risk of relapse is high especially in the setting of poor treatment compliance. Recent evidence however suggests that treatment discontinuation is possible after a prolonged period of normal aminotransferase activity without the need for liver biopsy prior to withdrawal.
- Open Access
- 4 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 5128
Telemedicine in Patients Affected by Chronic Liver Disease: A Scoping Review of Clinical Outcomes and the Devices Evaluated
For patients with chronic liver disease (CLD), telemedicine is emerging as a useful tool to prevent liver decompensation or hospitalization, allowing access to and the decentralization of care, even for patients with limited resources. However, research and attendant evidence are still lacking; thus, this review aims to systematically explore the topic of telemonitoring for CLD to describe the currently used tools and clinical outcomes. The review was conducted by using key terms on PubMed/EMBASE and searching for observational studies or clinical trials (according to PRISMA recommendations) that were published between 6 April 2013 and 6 April 2023 to keep the technological framework limited to the last 10 years. The studies were described and grouped according to the aim of telemonitoring, the underlying disease, and the tools adopted to achieve remote monitoring. A total of 32 articles met the inclusion criteria. Of these, 11 articles report the successful use of a telehealth program to support and improve access to care in the management of HCV-related cirrhosis, eight articles examine the efficacy of telemedicine for remote monitoring interventions to prevent or decrease the risk of decompensation in high-risk patients, and five articles examine improvements in the physical performance and quality of life of cirrhotic patients through telehealth rehabilitation programs. Four studies were completed during the recent COVID-19 pandemic. Telehealth has the potential to provide and expand treatment access and reduce barriers to care for the most disadvantaged patients and might be able to reduce the need for hospital readmission for CLD, though most practice to test feasibility is still in the pilot stage.
- 4 August 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (15) , 5128
Open AccessTelemedicine in Patients Affected by Chronic Liver Disease: A Scoping Review of Clinical Outcomes and the Devices Evaluated
For patients with chronic liver disease (CLD), telemedicine is emerging as a useful tool to prevent liver decompensation or hospitalization, allowing access to and the decentralization of care, even for patients with limited resources. However, research and attendant evidence are still lacking; thus, this review aims to systematically explore the topic of telemonitoring for CLD to describe the currently used tools and clinical outcomes. The review was conducted by using key terms on PubMed/EMBASE and searching for observational studies or clinical trials (according to PRISMA recommendations) that were published between 6 April 2013 and 6 April 2023 to keep the technological framework limited to the last 10 years. The studies were described and grouped according to the aim of telemonitoring, the underlying disease, and the tools adopted to achieve remote monitoring. A total of 32 articles met the inclusion criteria. Of these, 11 articles report the successful use of a telehealth program to support and improve access to care in the management of HCV-related cirrhosis, eight articles examine the efficacy of telemedicine for remote monitoring interventions to prevent or decrease the risk of decompensation in high-risk patients, and five articles examine improvements in the physical performance and quality of life of cirrhotic patients through telehealth rehabilitation programs. Four studies were completed during the recent COVID-19 pandemic. Telehealth has the potential to provide and expand treatment access and reduce barriers to care for the most disadvantaged patients and might be able to reduce the need for hospital readmission for CLD, though most practice to test feasibility is still in the pilot stage.